---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062036"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:14:24.039361+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q3 commercial revenue up 51% to $13.5M; net loss $8.7M

## Summary
- Commercial revenue $13.5M (+51% YoY); total revenue $13.6M; gross margin 84.5%.
- Net loss $8.7M ($0.34 loss per share) vs $5.6M loss a year ago; operating expenses $21.0M.
- Q4 2023 revenue guidance $15.3M-$16.3M (64%-73% YoY growth); full-year $51M-$53M.
- Secured up to $90M debt facility; $40M drawn at closing; cash $60.1M as of Sept 30.
- Expect FDA approval of RECELL GO by May 30, 2024; targeting profitability in 2025.

## SEC filing metadata
- accession: 0000950170-23-062036
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017023062036/0000950170-23-062036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017023062036/rcel-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062036
- JSON: https://secwatch.observer/filing/0000950170-23-062036.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062036.txt

## Key facts
- Earnings Releases
  AVITA Medical, Inc. reported the third quarter ended September 30, 2023 results: revenue $13.6 million, net income $8.7 million, EPS $0.34 per basic and diluted share. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $13.6 million
  - Net income: $8.7 million
  - EPS: $0.34 per basic and diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: $13.5 million in the three-months ended September 30, 2023, compared to $9.0 million in the same period in 2022. Total revenue, which includes BARDA revenue, increased by 50% to $13.6 million compared to $9.1 million in the same period in 2022. Gross profit margin increased by 1.3% to 84.5% compared to 83.2% for the third quarter of 2022. The increase was largely
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017023062036/0000950170-23-062036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.